Associated Papers
A study of elective genome sequencing and pharmacogenetic testing in an unselected population.
Cochran M et al.
Molecular Genetics & Genomic Medicine, 2021
Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.
Dron JS et al.
Bmc Medical Genomics, 2020
32041611 (PubMed )
Supplement: 12920_2020_669_MOESM1_ESM.xlsx › Supp_Table_4
Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
Lamiquiz-Moneo I et al.
Atherosclerosis, 2020
Evaluation of the role of STAP1 in Familial Hypercholesterolemia.
Danyel M et al.
Scientific Reports, 2019
Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes.
Cereda M et al.
Nature Communications, 2016
27377421 (PubMed )
Supplement: ncomms12072-s6.xlsx › Supplementary_Data_5
Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia.
Fouchier SW et al.
Circulation Research, 2014
25035151 (PubMed )
Supplement: 304660r2_online.pdf
Select a paper to view details